Geneius

Geneius is an immuno-oncology company that has developed an innovative autologous, adoptive T cell therapy technology which generates a more robust immune response to cancer compared to current approaches. Targeted DiversiTy re-educates the patient's own T cells to be responsive to multiple previously muted tumor antigens to deliver a stronger and... more durable immune response that is less susceptible to immune evasion. The company's breakthrough scalable manufacturing technology that enables the rapid optimization and expansion of subsets of T cells from a unit of patient blood. Proof-of-concept clinical studies by academic centers have shown highly durable response rates without significant toxicities in both hematologic and solid tumor cancers.Read More